Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Pfizer’s RSV Vaccine Abrysvo Now Available in Japan
Pfizer launched its respiratory syncytial virus (RSV) vaccine Abrysvo in Japan on May 31 for both maternal immunization and use in people 60 years of age and older. Abrysvo was approved in Japan in January for the prevention of RSV-associated…
To read the full story
Related Article
- Pfizer, ASKA to Co-Promote RSV Vaccine Abrysvo in Japan
March 9, 2026
- 63% of OB-GYN Clinics Adopt RSV Maternal Vaccine 1 Year after Launch
February 25, 2026
- Japan’s Maternal RSV Vaccine Uptake at 11.6%, Survey Finds
January 15, 2026
- Pediatric Specialist Pins Hope on Efficacy of Pfizer’s RSV Shot in Healthy Infants
March 12, 2024
- Expert Says RSV Shots Will Have Significant Clinical Impact, Urges Public Funding and NIP Inclusion
March 8, 2024
- KOL Highlights Need for Further RSV Epidemiological Research in Japan
February 15, 2024
- Japan Approves Pfizer’s RSV Jab, Ultragenyx’s Evkeeza, and More
January 19, 2024
BUSINESS
- SymBio Enrolls First Patient in US for PIII BCV Trial in Adenovirus Infection
March 18, 2026
- Incyte Looks to More Than Double International Business by 2030: CEO
March 18, 2026
- Oral Flu Drugs Prescribed to 2.46 Million in February as Cases Surge Again: Intage
March 17, 2026
- ADDP, Proteros Tie Up to Expand Drug Discovery Support
March 17, 2026
- Personal iPSC Service to Launch with Production Cost in the 10-Million-Yen Range
March 17, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…